SNWV

SANUWAVE's top line is genuinely impressive: revenue grew 35% to $44.1M with a 77.1% gross margin and positive operating income of $4.95M — a real, profitable medical-device franchise, not a story stock. After years of losses (revenue $13.0M→$44.1M and net losses every year FY2021–FY2024), FY2025 is the first GAAP-profitable year. That is the bull case, and it is not nothing.

The problem is the quality of that profit and the state of the balance sheet. The $11.8M net income is, in management's own words, 'largely driven by a non-cash change in the fair value of derivatives' — the MD&A's own reconciliation strips out an $8.1M derivative swing plus a $5.0M non-recurring license gain and $4.85M of stock comp. Strip those and the durable earnings power is closer to the $4.95M operating line, against which interest expense was $6.25M — meaning real interest cost exceeds operating income. The P/E of 24 is therefore being applied to a flattered number; the gap between $1.38 basic and $0.41 diluted EPS confirms heavy dilutive instruments overhanging the 8.59M-share count.